Skip to main content
A Better Partnership


Feb 2016
February 22, 2016

Medicare Part D Disclosure Now Due to the Centers for Medicare & Medicaid Services (CMS) on February 29, 2016

Because 2016 is a leap year, your Medicare Part D Disclosure to CMS may be due a day earlier than you are expecting.

Employers who sponsor group health plans that cover any prescription drugs generally must disclose whether the plan provides creditable or non-creditable prescription drug coverage to CMS within 60 days of the start of a new plan year. If your plan year begins on January 1, this normally means that you must file your disclosure with CMS by March 1. Since 2016 is a leap year, the 60-day deadline falls on Monday, February 29, 2016.

Filing is done electronically using the CMS Website. Instructions also are available there.

This filing requirement applies to health plans that cover anyone eligible for the Medicare Part D prescription drug program, whether as an active employee, spouse, dependent or retiree. There are limited exemptions for plans that contract with a Medicare Part D plan or directly with Medicare to become a Part D plan. Most employer-sponsored plans do not fall within these limited exceptions.

This disclosure is in addition to the Notice of Creditable (or Non-creditable) Coverage that you provide annually to Medicare-eligible participants. Remember also that if, after filing this disclosure, you terminate prescription drug coverage or change from creditable to non-creditable coverage (or vice versa), you must file a new electronic disclosure within 30 days and provide an updated notice to participants in your plan.

If you have any questions about the creditable coverage disclosure to CMS, or about Medicare Part D generally, please contact Norbert Kugele at or 616.752.2186; or April Goff at or 616.752.2154.

NOTICE. Although we would like to hear from you, we cannot represent you until we know that doing so will not create a conflict of interest. Also, we cannot treat unsolicited information as confidential. Accordingly, please do not send us any information about any matter that may involve you until you receive a written statement from us that we represent you.

By clicking the ‘ACCEPT’ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you.

Please click the ‘ACCEPT’ button if you understand and accept the foregoing statement and wish to proceed.



+ -